Artículos de revistas
We Know How To Prescribe Natalizumab For Multiple Sclerosis, But Do We Know How To Withdraw It?
Registro en:
Expert Review Of Neurotherapeutics. , v. 14, n. 2, p. 127 - 130, 2014.
14737175
10.1586/14737175.2014.874947
2-s2.0-84893060675
Autor
Fragoso Y.D.
Arruda N.M.
Arruda W.O.
Brooks J.B.B.
Correa E.C.
Damasceno A.
Damasceno C.A.
Ferreira M.L.B.
Giacomo M.C.B.
Gomes S.
Goncalves M.V.M.
Grzesiuk A.K.
Kaimen-Maciel D.R.
Lopes J.
Machado S.C.N.
Oliveira C.L.S.
Stella C.R.A.V.
Institución
Resumen
Natalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendations. © 2014 Informa UK, Ltd. 14 2 127 130 Nylander, A., Hafler, D.A., Multiple sclerosis (2012) J Clin Invest, 122, pp. 1180-1188 McCoyd, M., Update on therapeutic options for multiple sclerosis (2013) Neurol Clin, 31, pp. 827-845 McCormack, P.L., Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis (2013) Drugs, 73 (13), pp. 1463-1481 Fernández, O., Best practice in the use of natalizumab in multiple sclerosis (2013) Ther Adv Neurol Disord, 6, pp. 69-79 Sørensen, P.S., Bertolotto, A., Edan, G., Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) Mult Scler, 18, pp. 143-152 Pucci, E., Giuliani, G., Solari, A., Natalizumab for relapsing remitting multiple sclerosis (2011) Cochrane Database Syst Rev, 10, pp. CD007621 Fragoso, Y.D., Alves-Leon, S.V., Arruda, W.O., Natalizumab adverse events are rare in patients with multiple sclerosis (2013) Arq Neuropsiquiatr, 71, pp. 137-141 Damasceno, A., Von Glehn, F., Martinez, A.R., Early onset of natalizumab-related progressive multifocal leukoencephalopathy (2011) Mult Scler, 17, pp. 1397-1398 Baumgartner, A., Stich, O., Rauer, S., Clinical and radiological disease reactivation after cessation of long-Term therapy with natalizumab (2012) Int J Neurosci, 122, pp. 35-39 Rigau, V., Mania, A., Béfort, P., Lethal multiple sclerosis relapse after natalizumab withdrawal (2012) Neurology, 79, pp. 2214-2216 Marousi, S., Travasarou, M., Karageorgiou, C.E., Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS (2012) Neurology, 79, p. 2160 Berger, J.R., Centonze, D., Comi, G., Considerations on discontinuing natalizumab for the treatment of multiple sclerosis (2010) Ann Neurol, 68, pp. 409-411 Miravalle, A., Jensen, R., Kinkel, R.P., Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy (2011) Arch Neurol, 68, pp. 186-191 Borriello, G., Prosperini, L., Marinelli, F., Observations during an elective interruption of natalizumab treatment: A post-marketing study (2011) Mult Scler, 17, pp. 372-375 Papeix, C., Depaz, R., Tourbah, A., Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse (2011) Mult Scler, 17, pp. 1520-1522 Borriello, G., Prosperini, L., Mancinelli, C., Pulse monthly steroids during an elective interruption of natalizumab: A post-marketing study (2012) Eur J Neurol, 19, pp. 783-787 Magraner, M.J., Coret, F., Navarré, A., Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study (2011) J Neurol, 258, pp. 1805-1811 Rossi, S., Motta, C., Studer, V., Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab (2013) Eur J Neurol, 20, pp. 87-94 Havla, J., Gerdes, L.A., Meinl, I., De-escalation from natalizumab in multiple sclerosis: Recurrence of disease activity despite switching to glatiramer acetate (2011) J Neurol, 258, pp. 1665-1669 Gobbi, C., Meier, D.S., Cotton, F., Interferon beta 1b following natalizumab discontinuation: One year, randomized, prospective, pilot trial (2013) BMC Neurol, 13, p. 101 Cree, B., De Seze, J., Fox, R., RESTORE Study: Effects of a 24-week natalizumab treatment interruption on immune parameters and multiple sclerosis magnetic resonance imaging disease activity 2012 P06.168 (2012) Neurology, (78), pp. 106-168. , Meeting Abstracts 1 Comi, G., Gold, R., Dahlke, F., Overall safety and relapse outcomes in fingolimod-Treated patients previously treated with natalizumab in the 4-month open-label first study [poster (2013) European Neurology Society (ENS) Meeting Barcelona Spain Havla, J., Tackenberg, B., Hellwig, K., Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis (2013) J Neurol, 260, pp. 1382-1387 Daelman, L., Maitrot, A., Maarouf, A., Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal (2012) Mult Scler, 11, pp. 1647-1649 Sempere, A.P., Martín-Medina, P., Berenguer-Ruiz, L., Switching from natalizumab to fingolimod: An observational study (2013) Acta Neurol Scand, 128, pp. e6-e10 Centonze, D., Rossi, S., Rinaldi, F., Gallo, P., Severe relapses under fingolimod treatment prescribed after natalizumab (2012) Neurology, 79, pp. 2004-2005 Jander, S., Turowski, B., Kieseier, B.C., Hartung, H.P., Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod (2012) Mult Scler, 18, pp. 1650-1652